← Eichor
Study identifier: NCT07223008 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Bilateral Embolization of the Middle Meningeal Arteries for Refractory Chronic Migraine

Condition: Migraine · Chronic Migraine Headache · Refractory Migraine  ·  Sponsor: Johns Hopkins University

PhaseNA
Planned participants13
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

This study is to test the safety and feasibility of a procedure called embolization of the middle meningeal arteries (MMA), using a product called Onyx. Embolization creates a plug in the arteries. MMA embolization with Onyx is not approved for use in patients with migraines, but is currently used in patients with subdural hematomas. The FDA is allowing the use of Onyx in this study. It is thought that by using Onyx to block the middle meningeal arteries, the amount of migraine-causing substances which are released into the brain's bloodstream will be reduced. The company that manufactures Onyx, Medtronic, is providing the supplies for this study. Participants will be in the study for about 8 months after enrolling, including 6 months of follow up after the procedure. The participants will be asked to complete a daily headache diary and continue the participant's regular migraine medications. Participants will also have several clinic visits and be asked to provide blood samples for research.

This description comes directly from the study's public registry record.

Talk to the study team

Kelly Szajna  ·  000-000-0000  ·  ksajna1@jhmi.edu

Kallan Dirmeyer  ·  000-000-0000  ·  kdirmey1@jhmi.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Johns Hopkins MedicineBaltimore, Maryland, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07223008